BIO-Europe® 2011 program to highlight non-traditional partnerships and the year’s transformational deals

ZURICH & DUESSELDORF, Germany--(BUSINESS WIRE)-- Non-traditional healthcare alliances and the year’s prominent transformational deals will be the topics of in-depth discussion in the opening and keynote plenary sessions at BIO-Europe® 2011, being held October 31–November 2 at the CCD Congress Center in Duesseldorf, Germany.

In the opening plenary session, “Non-traditional Partnerships in the New Healthcare Ecosystem,” moderator Patrick Flochel of Ernst & Young will lead panelists Joerg Moeller, Bayer Pharma AG; Peer M. Schatz, QIAGEN; and Dan Zabrowski, Roche, in a compelling discussion about how diverse groups of players are developing alliances to meet the demands of personalized medicine.

“Partnerships with non-traditional players are becoming key for the development of important new treatment options,” said Carola Schropp, President of EBD Group. “BIO-Europe is an ideal venue for these players to present themselves and for traditional companies to scout for new partners.”

The ninth annual “A Day in the Life of Experienced Dealmakers” will focus on “Transformational Deals that Shaped the Industry in 2011.” Moderator Anton Gueth, Burrill & Company will join panelists Mercedes Diz, Almirall; Gunnar Gårdemyr, Nycomed; James O'Mara, Ironwood Pharmaceuticals; Catherine A. Sazdanoff, Takeda Pharmaceuticals; and Jack Tupman, Eli Lilly, in a revealing debate about the transformational deals in 2011 that have changed the competitive landscape and their companies’ position in the industry.

“I look forward to this discussion at BIO-Europe around transformational deals. The Nycomed acquisition is truly a transformational deal for Takeda and Nycomed, as it opens important new strategic opportunities for us,” said Gunnar Gårdemyr, Senior VP of Corporate Development/M&A at Nycomed. “Together with my Takeda counterpart, I look forward to discussing how the deal came about, what this collaboration means for both parties and how it creates additional opportunities to build value as one company.”

BIO-Europe is Europe's largest partnering event serving the global biotechnology industry. BIO-Europe 2010 saw 14,661 one-to-one meetings conducted by 2,906 attendees from 1,688 companies. The event features partneringONE®, the industry's most advanced web-based partnering system, enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward.

For more information or to register, visit www.ebdgroup.com/bioeurope

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America™, the fastest growing partnering event in North America
  • EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
  • Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world.

Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.



CONTACT:

EBD Group
Tilton Little, +1 415-410-5410
[email protected]

KEYWORDS:   Europe  Germany  Switzerland

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.